|
 |
Prednisolone sodium phosphateThis page contains recent news articles, when available, and an overview of Prednisolone sodium phosphate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Prednisolone sodium phosphate (when available) Prednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders. Mechanism Of Action: Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression. News Articles on Prednisolone KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results ... - Feb 15, 2008 ...including: Diltiazem HCL extended release capsules, Nystatin Topical Powder and a new formulation of Prednisolone Sodium Phosphate. PR Newswire (press release), biomarin Announces Third Quarter 2007 Financial Results - Nov 1, 2007 ...including Orapred(R) (prednisolone sodium phosphate oral solution) and Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets). CNNMoney.com BioMarin Announces First Quarter 2007 Financial Results - Apr 30, 2007 PR Newswire (press release),...including Orapred(R) (prednisolone sodium phosphate oral solution) and Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets). Orapred ODT Tastes Good - Mar 29, 2007 Drug Newswire (press release),Orapred ODT(TM) (Prednisolone sodium phosphate orally disintegrating tablets) is a prescription drug product indicated for the control of severe or Orapred ODT Tastes Good - Mar 29, 2007 PR Newswire (press release),Important Safety Information Orapred ODT(TM) (Prednisolone sodium phosphate orally disintegrating tablets) is a prescription drug product indicated for the BioMarin Announces Third Quarter 2006 Financial Results Nov 1, 2006 ...million, respectively, and include royalties on net product sales of the Orapred product line, including Orapred(R) (prednisolone sodium phosphate oral solution ... -PR Newswire (press release), FDA Sends BioMarin Warning Letter Over OrapredCI Product Website Oct 12, 2006 ...which markets OrapredCI (prednisolone sodium phosphate oral solution) (Orapred) on behalf of BioMarin, that the Division of Drug Marketing, Advertising, and ... -PharmaLive.com (press release), BioMarin Announces US Launch of Orapred ODT Through Alliant ... Aug 28, 2006 ...(Nasdaq and SWX: BMRN - News News) today announced that Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets), the first FDA-approved ... -Yahoo! News BioMarin Announces US Launch of Orapred ODT Through Alliant ... Aug 28, 2006 ...today announced that Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets), the first FDA-approved orally disintegrating tablet form of ... -PharmaLive.com NutraCea to Present at Roth Capital Growth Conference and ... Aug 29, 2006 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) recently announced that Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets), the first FDA ... -Financial News USA Orapred ODT Arrives in US Market Aug 28, 2006 Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets) is marketed in the United States by Alliant Pharmaceuticals, pursuant to a ... -Yahoo! News NutraCea to Present at Roth Capital Growth Conference and ... 29 Aug 2006 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) recently announced that Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets), the first FDA ... -Financial News USA BioMarin Announces US Launch of Orapred ODT Through Alliant ... Aug 28, 2006 ...(Nasdaq and SWX: BMRN - News News) today announced that Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets), the first FDA-approved ... -Yahoo! News BioMarin Announces Second Quarter 2006 Financial Results Aug 2, 2006 ...milestone payment of $7.5 million from Alliant Pharmaceuticals, following FDA approval of Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating ... -Yahoo! News Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ... May 11, 2006 Additionally, BioMarin has rights to receive payments and royalties related to Orapred(R) (prednisolone sodium phosphate oral solution). ... - Genetic Engineering News BioMarin Announces First Quarter 2006 Financial Results May 3, 2006 Net sales of Orapred(R) (prednisolone sodium phosphate oral solution), including the branded and authorized generic products, were $2.0 million for the first ... - PR Newswire BioMarin to Present at the Rodman and Renshaw 3rd Annual Global ... May 8, 2006 Additionally, BioMarin has rights to receive payments and royalties related to Orapred® (prednisolone sodium phosphate oral solution). ... - Yahoo! News BioMarin and Alliant Pharmaceuticals Announce North American ... Mar 15, 2006 ...entered into a licensing and acquisition agreement pertaining to exclusive North American rights to the Orapred(R) (prednisolone sodium phosphate oral solution ... - PR Newswire BioMarin Announces Closing of $295 Million Concurrent Public ... Mar 30, 2006 Additionally, BioMarin has rights to receive payments and royalties related to Orapred(R) (prednisolone sodium phosphate oral solution). ... - PR Newswire BioMarin and Serono Announce Positive Results From Phase 3 ... Mar 15, 2006 ...and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution ... - PR Newswire BioMarin’s Shares Move On Phenoptin Phase III Success Mar 16, 2006 ...and a potential launch of Phenoptin, it made sense for BioMarin to license out North American rights to the Orapred (prednisolone sodium phosphate) product line ... - BioWorld Online (subscription) BioMarin and Alliant in licensing deal Mar 17, 2006 Orapred is the leading brand of liquid prednisolone sodium phosphate used to treat exacerbations of asthma and other inflammatory diseases and conditions in ... - Pharmaceutical Business Review BioMarin and Serono Announce Positive Results From Phase 3 ... Mar 15, 2006 ...and commercialized by BioMarin, Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred® (prednisolone sodium phosphate oral solution) for ... - Yahoo! News BioMarin Announces Fourth Quarter and Year-End 2005 Financial ... Feb 23, 2006 Net sales of Orapred(R) (prednisolone sodium phosphate oral solution), including the branded and authorized generic products, were $0.4 million for the fourth ... - PR Newswire, BioMarin to Present at Cowen & Co. 26th Annual Health Care ... Feb 27, 2006 ...and commercialized by BioMarin, Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred® (prednisolone sodium phosphate oral solution) for ... - Yahoo! News BioMarin to Present at Cowen & Co. 26th Annual Health Care ... Feb 27, 2006 ...and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution ... - PharmaLive.com, BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 30, 2006 ...and commercialized by BioMarin, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred(R) (prednisolone sodium phosphate oral solution ... - MSN Money BioMarin Receives FDA Fast Track Designation for Phenoptin for PKU Jan 25, 2006 ...and commercialized by BioMarin, Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), and Orapred® (prednisolone sodium phosphate oral solution) for ... - Yahoo! News Brand Names/Synonyms: Prednisolone sodium phosphate is also known by the following brand names and/or synonyms.Delta.-Cortef; .Delta.-Stab; A-Methapred; Ak-Pred; Ak-Tate; Alphadrol; Articulose-50; CCRIS 980; Chloroptic-P S.O.P.; Co-Hydeltra; Codelcortone; Cordrol; Cortalone; Cotogesic; Cotolone; Decaprednil; Decortin H; Delcortol; Delta F; Delta-Cortef; Delta-Stab; Deltacortenol; Deltacortril; Deltacortril Enteric; Deltahydrocortisone; Deltasolone; Deltisilone; Depo-Medrol; Derpo Pd; Dexa-Cortidelt Hostacortin H; Di-Adreson F; Dicortol; Donisolone; Dydeltrone; Eazolin D; Econopred; Econopred Plus; Erbacort; Erbasona; Estilsona; Fernisolone; Fernisolone P; Fernisolone-P; Flamasone; HSDB 3385; Hostacortin H; Hydeltra; Hydeltra-Tba; Hydeltrasol; Hydeltrone; Hydrodeltalone; Hydrodeltisone; Hydroretrocortin; Hydroretrocortine; I-Pred; Inflamase Forte; Inflamase Mild; K 1557; Key-Pred; Klismacort; Lentosone; Lite Pred; M-Predrol; Medrol; Medrol Acetate; Metacortandralone; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Sodium Succinate; Meti-Derm; Meticortelone; Meticortelone;Sterolone; Metreton; NSC 9120; NSC9900; Nisolone; Nor-Pred T.B.A.; Ocu-Pred; Ocu-Pred Forte; Ophtho-Tate; Orapred; PRDL; Panafcortelone; Paracortol; Paracotol; Pediapred; Precortalon; Precortancyl; Precortilon; Precortisyl; Pred Forte; Pred Mild; Predair; Predair A; Predair Forte; Predalone 50; Predalone T.B.A.; Predate Tba; Predate-50; Predcor-25; Predcor-50; Predcor-Tba; Predisolone Sodium Phosphate; Predne-Dome; Prednelan; Predni-Dome; Prednicen; Predniliderm; Predniretard; Prednis; Prednisolona [Inn-Spanish]; Prednisolone; Prednisolone Acetate; Prednisolone Sodium Phosphate; Prednisolone Tebutate; Prednisolone [Ban:Inn:Jan]; Prednisolonum [Inn-Latin]; Predonin; Predonine; Prelone; Prenolone; Rolisone; Scherisolon; Solone; Solu-Medrol; Steran; Sterane; Sterolone; Supercortisol; Ulacort; Ultra Pred; Ultracorten H; Ultracortene H; Ultracortene-H; Ultracortene-Hydrogen Drug Category: Prednisolone sodium phosphate is categorized under the following by the FDA: Antineoplastic Agents; Glucocorticoids; Anti-inflammatory Agents; Adrenergic Agents; ATC:A07EA01; ATC:C05AA04; ATC:D07AA01; ATC:D07AA03; ATC:D07AC14; Dosage Forms: SOLUTION Absorption: Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration Interactions: Not Available Chemical IUPAC Name: 11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |